A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma.
| Autor: | English PA; Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121, USA., Williams JA; Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121, USA., Martini JF; Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121, USA., Motzer RJ; Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA., Valota O; Pfizer Oncology, via AM Mozzoni 12, Milan, 20152, Italy., Buller RE; Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Future oncology (London, England) [Future Oncol] 2016 Jan; Vol. 12 (2), pp. 175-82. Date of Electronic Publication: 2015 Dec 17. |
| DOI: | 10.2217/fon.15.290 |
| Abstrakt: | Aim: Assess patient-level utility of suggested pretreatment biomarkers of sunitinib in advanced renal cell carcinoma. Patients & Methods: Kaplan-Meier analysis of data from a randomized, Phase II study (n = 292) suggested baseline predictive value for circulating soluble Ang-2 and MMP-2 and HIF-1α percentage of tumor expression. Using this dataset, the sensitivity, specificity and area under the curve (AUC) were calculated, using receiver operating characteristic (ROC) curves. Results: Based on a ROC (sensitivity vs 1 - specificity) threshold AUC value of >0.8, neither Ang-2 (0.67) nor MMP-2 (0.65), nor HIF-1α percentage of tumor expression (0.65), performed appropriately from a patient-selection standpoint. Conclusion: To properly assess potential biomarkers, sensitivity and specificity characteristics should be obtained by ROC analysis. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|